Genentech, Inc Patent Portfolio Statistics

tip_user1

Genentech, Inc.

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Genentech, Inc. look like?

Assignee Art Units
Total Applications: 2,052 1,569,322
Granted Patents: 889 797,535
Grant Index 55.84% ↓ 66.88%
Abandoned/Rejected Applications: 703 (44.16%) 394,891 (33.12%)
In-Process Applications: 458 376,896
Average Grant Time: 3.63 Years ↑ 2.76 Years
Average Office Actions: 2.05 ↑ 1.69

Which Technology Area Genentech, Inc. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1644 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 213
1642 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 182
1643 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 160
1646 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 146
1647 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 130

How many patents are Genentech, Inc. filing every year?

Year Total Applications Predicted
2022 0* 514
2021 24* 445
2020 31 357
2019 35 35
2018 22 –
2017 35 –
2016 33 –
2015 50 –
2014 59 –
2013 79 –

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Genentech, Inc. in USPTO?

Publication number: US20220073623A1
Application number: 17/535,898

Abstract:
The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, non-small cell lung cancer (NSCLC). The invention provides methods of treating NSCLC, methods of determining whether a patient suffering from NSCLC is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from NSCLC to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from NSCLC, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor cells and/or tumor-infiltrating immune cells).

Publication date: 2022-03-10
Applicant: Genentech, Inc.
Inventors: Kowanetz Marcin

Publication number: US20220064286A1
Application number: 17/526,338

Abstract:
The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Publication date: 2022-03-03
Applicant: Genentech, Inc.
Inventors: Liang Wei-Ching

Publication number: US20220152030A1
Application number: 17/524,050

Abstract:
Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.

Publication date: 2022-05-19
Applicant: Genentech, Inc.
Inventors: Andrew Mark Merchant

How are Genentech, Inc.’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/535,898 Therapeutic And Diagnostic Methods For Cancer Docketed New Case – Ready for Examination OPAP Central, Docket
17/526,338 Anti-Tigit Antibodies And Methods Of Use Expressly Abandoned — During Examination OPAP Central, Docket
17/524,050 Methods And Compositions Comprising A Krasg12C Inhibitor And A Vegf Inhibitor For Treating Solid Tumors – OPAP Central, Docket
17/454,015 Methods Of Making Antibodies Docketed New Case – Ready for Examination OPAP Central, Docket
17/517,103 Process For Making Arylomycin Ring Analogs Docketed New Case – Ready for Examination OPAP Central, Docket